JULIO EDUARDO
NUÑEZ VILLOTA
TITULAR DE UNIVERSIDAD
University of Copenhagen
Copenhague, DinamarcaPublicaciones en colaboración con investigadores/as de University of Copenhagen (5)
2024
-
Non-invasive heart failure monitoring: leveraging smart scales and digital biomarkers to improve heart failure outcomes
Heart Failure Reviews, Vol. 29, Núm. 5, pp. 1145-1156
-
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
The Lancet, Vol. 403, Núm. 10437, pp. 1635-1648
-
The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases
Matrix Biology, Vol. 132, pp. 1-9
2023
-
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes and Metabolism, Vol. 49, Núm. 2
-
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Cardiovascular Diabetology, Vol. 22, Núm. 1